Screen for depression in RA patients! From the #DANBIO registry of 11,000 pts, they found 6X ⬆️mortality in pts w/#RA and #depression . The mortality curve separates early. #Plenary OP0067 @rheumnow #EULAR2022 https://t.co/qfjyejGVzQ

#EULAR2022 POS0241 shows JAKi ⬇️ pain catastrophization/central sensitization in RA patient via CSI (Central Sensitization Inventory) and (PCS) Pain Catastrophizing Scale. No decrease of articular inflammation on ultrasound with JAKi shown, but study had just 22 pts @RheumNow

#EULAR2022 OP0066 French retrospective obs study 2019-2021 with 73 cases of Whipples disease treated for rheum disease ▶️M/F ratio 3, middle aged ▶️1/2 met RA criteria ▶️Peripheral jts, 1/3 had axial involvement ▶️Rx: HCQ, Doxi - 80% cured, DMARD stopped in >90% cases @RheumNow https://t.co/t7zlDrPfJB

NORD-STAR results. Biologic + MTX combo seemed better than slightly strange "conventional"(ACT) group of MTX + oral steroids or triple therapy + IA injections @RheumNow #EULAR2022 OP0058 https://t.co/tOfTlcplFR https://t.co/CvtvuVn5Xj

• EULAR Abstract Archive

#EULAR2022 POS0235: Filgotinib Safety in RA for Median 2.2 years: ▶️No new safety concerns from 2020 report with shorter f/u ▶️Adverse events stable, or decreased, from early studies @Rheumnow https://t.co/DO15Tqim4n

@Rheumnow #EULAR2022 POS0240 ▶️ In 2021, 73.6% of Belgian RA patients staring a JAKi, started a 2nd generation JAKi (UPA, FIL). Predictors for 1st generation usage (BAR, TOFA): older age, prior DMARD therapies. What would you start as a first JAKi?

Household Cleaning is dirty business at least if you have #rheumatoid #arthritis as silica exposure from laundry and cleaning products were associated with RA ILD. #EULAR opening day. #ClinicalPearl #EULAR2022 @RheumNow #OP0006 https://t.co/OJQMy9Fe9m

ACR21: conditionally recommends against steroids with starting csDMARD #EULAR2022 recommends with rapid GC dose reduction and discontinuation Which is better recommendation? @RheumNow

#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI

After the #EULAR2022 Recommendations session, it begs the question - Do we follow it? In Germany, the answer is sometimes Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD POS0234 @Rheumnow https://t.co/0DaP5b7Htc